

BOND LABORATORIES, INC.  
 Form 4  
 September 19, 2012

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL  
 OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Vicis Capital, LLC

2. Issuer Name and Ticker or Trading Symbol  
 BOND LABORATORIES, INC.  
 [BNLB]

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)

(Last) (First) (Middle)  
 445 PARK AVENUE,, SUITE 1901  
 (Street)

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 09/17/2012

\_\_\_\_ Director  
 \_\_\_\_ Officer (give title below)  
 \_\_\_X\_\_\_ 10% Owner  
 \_\_\_\_ Other (specify below)

NEW YORK, NY 10022

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 \_\_\_ Form filed by One Reporting Person  
 \_\_\_X\_\_\_ Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |     |       |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|-----|-------|
|                                 |                                      |  |                                | (A) or (D)  | Code  | V  | Amount                            | (D) | Price |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.** SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security | 2. Conversion or Exercise | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any | 4. Transaction Code | 5. Number of Derivative Securities | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) |
|---------------------------------|---------------------------|--------------------------------------|-----------------------------------|---------------------|------------------------------------|--|---|
|---------------------------------|---------------------------|--------------------------------------|-----------------------------------|---------------------|------------------------------------|--|---|

Edgar Filing: BOND LABORATORIES, INC. - Form 4

| (Instr. 3)   | Price of<br>Derivative<br>Security | (Month/Day/Year) | (Instr. 8) | Acquired (A) or<br>Disposed of (D)<br>(Instr. 3, 4, and 5) |           | Date<br>Exercisable | Expiration<br>Date | Title           | Amo<br>Num<br>Shar |
|--|------------------------------------|------------------|------------|--|-----------|---------------------|--------------------|-----------------|--------------------|
|  |                                    |                  |            | Code   | V (A) (D) |                     |                    |                 |                    |
| Series C<br>Convertible<br>Pref. Stock,<br>\$.01 par<br>value per<br>share | (3)                                | 09/17/2012       | S          | (A)  | 125       | (2)                 | (4)                | Common<br>Stock | 5,000              |
| Warrant to<br>Purchase<br>Common<br>Stock                                  | \$ 0.3                             | 09/17/2012       | S          | (A)  | 2,500,000 | (2)                 | 11/15/2015         | Common<br>Stock | 2,500,000          |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| Vicis Capital, LLC<br>445 PARK AVENUE,<br>SUITE 1901<br>NEW YORK, NY 10022        |               | X         |         |       |
| Vicis Capital Master Fund<br>445 PARK AVENUE,<br>SUITE 1901<br>NEW YORK, NY 10022 |               | X         |         |       |

## Signatures

|   |            |
|---|------------|
| /s/ Andrew Comito, Compliance Officer, Vicis Capital, LLC               | 09/18/2012 |
| __Signature of Reporting Person   | Date       |
| /s/ Andrew Comito, Authorized Representative, Vicis Capital Master Fund | 09/18/2012 |
| __Signature of Reporting Person   | Date       |

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents the indirect holdings of Vicis Capital LLC. All of the foregoing represents securities held directly by Vicis Capital Master Fund. Vicis Capital LLC acts as investment advisor to Vicis Capital Master Fund and therefore has voting and dispositive power over all the foregoing shares. For the purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Vicis Capital LLC may be deemed to be the beneficial owner of, but hereby disclaims such beneficial ownership of, the foregoing shares.
- (2) Immediately.
- (3) Each share of the Series C Convertible Preferred Stock currently converts on a 1-for-40,000 basis.

Edgar Filing: BOND LABORATORIES, INC. - Form 4

(4) None.

(5) Vicis Capital Master Fund sold these shares of Series C Convertible Preferred Stock and this warrant in a private transaction for aggregate consideration of \$300,000.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.